CS2009是一款同时靶向PD-1、CTLA-4和VEGFA的药物，具有潜在同类首创的作用机理。 CS2009拥有平衡的抗PD-1和抗CTLA-4亲和力，可以同时结合PD-1、CTLA-4及VEGFA ...

Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive ...

For the preclinical study, mice were implanted with either CT26 or Colon26 cells, both mouse models of MSS/MMRp CRC. The mice were treated with anti-CTLA-4 and either daily or biweekly DNase I.